MedTrace Logo

The PAH Disability and Bothersomeness Questionnaire

NCT03235401 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2017-08-01

No results posted yet for this study

Summary

To develop a patient-reported questionnaire to investigate the impact of PAH (pulmonary arterial hypertension) on patients' daily lives in terms of bothersomeness and disability.

Conditions

  • Pulmonary Arterial Hypertension (PAH)

Interventions

OTHER

37-items questionnaire

Patient will answer the PAH-DBoQ questionnaire

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Soladis

    collaborator INDUSTRY

  • Interlis

    collaborator UNKNOWN

  • Association de Recherche en Physiopathologie Respiratoire

    lead OTHER

Principal Investigators

  • Olivier SITBON, PHD · Service de Pneumologie et Soins Intensifs, Hôpital de Bicêtre, Université Paris-Sud France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-16
Primary Completion
2017-12-16
Completion
2018-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235401 on ClinicalTrials.gov